Korunmuş ejeksiyon fraksiyonlu kalp yetmezliği
Öz
Anahtar Kelimeler
Kaynakça
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37 ( 27): 2129-200.
- Oren O, Goldberg S. Heart failure with preserved ejection fraction: diagnosis and management. Am J Med 2017; 130 ( 5): 510-6.
- Borlaug BA, Lam CSP, Roger VL, Rodeheffer RJ,Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease. J Am Coll Cardiol 2009; 54 (5): 410-8.
- Melenovsky V, Borlaug BA, Rosen B. et al. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community. The role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007; 49 (2): 198-207.
- Gorter TM, Hoendermis ES, van Veldhuisen DJ et al. Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail 2016;18 (12): 1472-87.
- Lam CSP, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction. A community-based study. J Am Coll Cardiol 2009; 53 (13): 1119-26.
- Van Linthout S, Tschöpe C. Inflammation – Cause or consequence of heart failure or both? Curr Heart Fail Rep 2017; 14 (4): 251-65.
- Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62 (4): 263-71.
Ayrıntılar
Birincil Dil
Türkçe
Konular
Sağlık Kurumları Yönetimi
Bölüm
Olgu Sunumu
Yazarlar
Şükriye Miray Kılınçer Bozgül
0000-0002-3995-5096
Türkiye
Devrim Bozkurt
*
0000-0003-4557-3390
Türkiye
Yayımlanma Tarihi
20 Ocak 2021
Gönderilme Tarihi
6 Nisan 2020
Kabul Tarihi
28 Ağustos 2020
Yayımlandığı Sayı
Yıl 1970